Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Phase 2

Active, not recruiting

Conditions: Bronchopulmonary Dysplasia of Newborn

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2020-06-25

Last Posted Date: 2024-12-18

Lead Sponsor: Christoph Hornik

Target Recruit Count: 120

Registration Number: NCT04447989

Locations: 🇺🇸
Women's Hospital of Texas, Houston, Texas, United States
🇺🇸
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States

and more 22 locations

Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension

Phase 1

Completed

Conditions: Persistent Pulmonary Hypertension

Interventions: Drug: Milrinone
Drug: Sildenafil

First Posted Date: 2020-05-18

Last Posted Date: 2020-05-18

Lead Sponsor: Rania Ali El-Farrash

Target Recruit Count: 40

Registration Number: NCT04391478

Sildenafil for Treatment of Choroidal Ischemia

Phase 2

Active, not recruiting

Conditions: Vitelliform Macular Dystrophy
Age-related Macular Degeneration
Retinitis Pigmentosa
Central Serous Retinopathy
Choroidal Ischemia

Interventions: Other: Standard of Care Sildenafil
Drug: Sildenafil
Diagnostic Test: Ocular Coherence Tomography-Angiography (OCT-A)
Other: Visual Acuity (VA)

First Posted Date: 2020-04-22

Last Posted Date: 2023-10-23

Lead Sponsor: Columbia University

Target Recruit Count: 25

Registration Number: NCT04356716

Locations: 🇺🇸
Columbia University Medical Center, Edward Harkness Eye Institute, New York, New York, United States

Sildenafil in Acute Pulmonary Embolism

Early Phase 1

Completed

Conditions: Pulmonary Embolism

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2020-02-25

Last Posted Date: 2020-02-25

Lead Sponsor: University of Aarhus

Target Recruit Count: 20

Registration Number: NCT04283240

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Macitentan
Drug: Rosuvastatin
Drug: Sildenafil
Drug: Riociguat

First Posted Date: 2019-12-26

Last Posted Date: 2022-05-25

Lead Sponsor: Actelion

Target Recruit Count: 47

Registration Number: NCT04211272

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

PDE5i Use in Renal Transplant Recipients

Not Applicable

Withdrawn

Conditions: Renal Transplant Failure

Interventions: Drug: Sildenafil

First Posted Date: 2019-10-10

Last Posted Date: 2024-05-16

Lead Sponsor: University of British Columbia

Registration Number: NCT04122105

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy

Withdrawn

Conditions: High Risk Pregnancy

Interventions: Drug: Sildenafil

First Posted Date: 2019-10-01

Last Posted Date: 2022-03-31

Lead Sponsor: Fayoum University Hospital

Registration Number: NCT04110444

Locations: 🇪🇬
sahar M.Y elbaradie, Fayoum, Egypt

Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease

Phase 3

Withdrawn

Conditions: Single-ventricle
Pulmonary Hypertension
Univentricular Heart

Interventions: Drug: Sildenafil
Drug: Placebos

First Posted Date: 2019-06-25

Last Posted Date: 2023-05-15

Lead Sponsor: University Hospital, Montpellier

Registration Number: NCT03997097

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

Early Phase 1

Completed

Conditions: Intrapulmonary Arteriovenous Anastamosis
Patent Foramen Ovale

Interventions: Other: Placebo
Drug: Sildenafil

First Posted Date: 2019-05-10

Last Posted Date: 2023-08-14

Lead Sponsor: University of Oregon

Target Recruit Count: 82

Registration Number: NCT03945643

Locations: 🇺🇸
Cardiorespiratory and Pulmonary Physiology Lab, Eugene, Oregon, United States

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

Phase 2

Completed

Conditions: Small Vessel Cerebrovascular Disease

Interventions: Drug: Placebo
Drug: Cilostazol
Drug: Sildenafil

First Posted Date: 2019-02-26

Last Posted Date: 2023-02-24

Lead Sponsor: University of Oxford

Target Recruit Count: 75

Registration Number: NCT03855332

Locations: 🇬🇧
University of Oxford, Oxford, Oxon, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy